AGM Statement
21 Maio 2009 - 3:00AM
UK Regulatory
TIDMGTX
RNS Number : 6001S
Genetix Group PLC
21 May 2009
Genetix Group plc
=-AGM Statement--
New Milton, UK, 21 May 2009 - Genetix Group plc (AIM:GTX), the cell imaging and
analysis group will hold its Annual General Meeting (AGM) today at 11.30 a.m.
During the course of the meeting Charles de Rohan, Chief Executive of Genetix,
will make the following statement to shareholders:
"Genetix has made a positive start to the year and is trading in line with our
expectations.
While no company is immune from the effects of the global economic conditions,
our tightly managed business coupled with our products delivering tangible
benefits to our customers, is proving resilient in meeting these challenges.
The successful rebalancing of our product portfolio over the last few years
means the Group is in a strong position to capitalise on the growth within its
chosen markets of biopharmaceutical drug discovery and diagnostics - markets
which allow us to play to our strengths in imaging and intelligent analysis.
We are excited about the opportunities that our recent acquisition of SlidePath
present, allowing us to accelerate and strengthen our presence in the growing
digital pathology market. Combining SlidePath's cutting edge products and
technologies with our sales and customer support infrastructure in Europe, the
United States and Japan, along with our strong customer relationships with
diagnostics and pharmaceutical companies will enhance our position in this
exciting market."
=-Ends--
+------------------------------------+------------------------------------+
| Genetix Group plc | |
+------------------------------------+------------------------------------+
| Charles de Rohan, Chief Executive | Tel: +44 (0) 1425 624600 |
+------------------------------------+------------------------------------+
| Andrew Kellett, Finance Director | |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Financial Dynamics | |
+------------------------------------+------------------------------------+
| Jonathan Birt / Susan Quigley | Tel: +44 (0) 20 7831 3113 |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Piper Jaffray Ltd. | |
+------------------------------------+------------------------------------+
| James Steel | Tel: +44 (0) 20 3142 8700 |
+------------------------------------+------------------------------------+
The release will be available on the Company's website: www.genetix.com
Notes to Editors
About Genetix Group plc
Headquartered in New Milton, UK, with offices in the UK, US, Germany, Ireland
and Japan, and quoted on the AIM (GTX: AIM), Genetix provides scientists and
clinicians with unrivalled solutions for imaging and intelligent image analysis
in the life science and diagnostic markets.
In life sciences, the company's systems set industry standards for accurate
selection of microbial colonies, and for screening and selection of mammalian
secretory cell lines. Other systems evaluate the response of cells to potential
therapeutic agents and quantify tissue biomarkers.
In diagnostics, Genetix holds a leading position in genetic testing with
thousands of the company's platforms used in laboratories worldwide.
Through its expertise in robotics, cell and molecular biology, image analysis
and interpretation, supported by a strong IP portfolio, Genetix is committed to
the continual development of innovative solutions.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMAMMATMMTTBPL
Genetix Grp (LSE:GTX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Genetix Grp (LSE:GTX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Genetix Grp da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Genetix